Format

Send to

Choose Destination
See comment in PubMed Commons below
Trends Pharmacol Sci. 1990 Apr;11(4):150-5.

Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors.

Author information

1
Department of Pharmacology, University of Washington, Seattle 98195.

Abstract

Primary sequence information has been reported for more than 15 different mammalian cyclic nucleotide phosphodiesterases. Moreover, recent observations suggest that many of these isozymes are selectively expressed in a limited number of cell types. The fact that nearly all these different phosphodiesterases have unique primary sequences in their catalytic or regulatory domains and that they are often selectively expressed implies that it may be possible to modulate individual isozymes using specific drugs. Joe Beavo and David Reifsnyder summarize much of the evidence that has led to our current understanding of multiple isozymes of phosphodiesterase, with emphasis on aspects that may be relevant to drug design. They also discuss why many previous attempts to isolate isozyme-selective inhibitors may have failed.

PMID:
2159198
DOI:
10.1016/0165-6147(90)90066-H
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center